Merck & Company
2000 Galloping Hill Road
About Merck & Company
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
2987 articles with Merck & Company
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women Who Responded to Platinum-Based Chemotherapy
LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
8/13/2019Merck's Keytruda has become one of the best-selling drugs in the world. Last year, it generated more than $7 billion in revenue for Merck and that is only predicted to grow, particularly as the drug wins approval for new indications.
Harvard, Merck to collaborate on research led by Harvard immunologist Arlene Sharpe, seeking to identify new pathways for the treatment of cancer
Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer
The study is expected to enroll approximately 80 patients in the U.S., United Kingdom, Korea and Taiwan.
Privately-held Oncologie will conduct a Phase II study of the combination study for patients who have failed at least one line of treatment for gastric or gastroesophageal cancer.
8/12/2019Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg twice daily in men with metastatic castration-resistant prostate cancer who have a *homologous recombination repair gene mutation and have failed prior treatment with new hormonal anticancer agents.
LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced positive results from the Phase 3 PROfound trial of LYNPARZA in men with metastatic castration-resistant prostate cancer who have an homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal anticancer treatments.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum has been promoted to vice president, Investor Relations, effective Aug. 19, 2019
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics, Inc. announced that its anti-Dickkopf-1 antibody, DKN-01, in combination with Merck's anti-PD-1 antibody, Keytruda®, demonstrated higher survival and objective response outcomes in patients with advanced gastroesophageal junction and gastric cancer whose tumors expressed high levels of DKK1.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
Swim Across America Receives Additional $2 Million Donation from Merck to Accelerate Cancer Research
The contributions allow Swim Across America to further expand its charity swim program to raise more funds for cancer research.
KEYTRUDA Now Approved for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus in Patients Whose Tumors Express PD-L1 (CPS ≥10) With Disease Progression After One or More Prior Lines of Systemic Therapy
7/31/2019The U.S. Food and Drug Administration approved the anti-PD-1 therapy as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced financial results for the second quarter of 2019.
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC)
KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Statistically Significant Improvement in pCR Rates as Neoadjuvant Therapy for TNBC Regardless of PD-L1 Status
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial